Pregnancy Vitamin D Supplementation and Childhood Bone Mass at Age 4 Years: Findings From the Maternal Vitamin D Osteoporosis Study (MAVIDOS) Randomized Controlled Trial

Elizabeth Curtis, Rebecca J Moon, Stefania D’Angelo, Sarah Crozier, Nicholas Bishop, Jaya Sujatha Gopal‐Kothandapani, Stephen Kennedy, Aris T. Papageorghiou, Robert Fraser, Saurabh Gandhi, Inez Schoenmakers, Ann Prentice, Hazel Inskip, Keith M. Godfrey, M K Javaid, Richard Eastell, Cyrus Cooper, Nicholas C. Harvey, the Mavidos Trial GroupJBMR 2022 · DOI

TL;DR

Supplementing pregnant mothers with vitamin D (1000 IU/day) led to increased bone mineral density in their children at age 4, suggesting a lasting skeletal benefit. This effect was particularly pronounced in children with lower milk intake and physical activity, highlighting potential synergistic interactions.

What Problem Does This Paper Address?

The skeletal health of children is influenced by factors during pregnancy, including maternal vitamin D status. While observational studies have suggested a link between higher maternal vitamin D levels and better childhood bone development, intervention studies have been limited. The MAVIDOS trial initially found no overall effect of vitamin D supplementation on neonatal bone mass, but a secondary analysis showed a benefit for winter-born babies. This follow-up study aimed to determine if this beneficial effect on bone mass persists into early childhood (age 4) and to explore potential interactions with child's diet and activity levels.

Methods

This study is a follow-up of the MAVIDOS randomized controlled trial. Pregnant women with adequate vitamin D levels (25-100 nmol/L) were randomized to receive either 1000 IU/day of cholecalciferol (vitamin D3) or a placebo from 14 weeks of gestation until delivery. The current study focused on offspring born at the Southampton research center, assessing them at age 4. Key measurements included anthropometry (height, weight, BMI) and dual-energy X-ray absorptiometry (DXA) to assess bone mineral content (BMC), areal bone mineral density (aBMD), and bone area (BA) of the whole body less head (WBLH). Body composition (lean mass, fat mass) and grip strength were also measured. Statistical analyses included comparisons between groups, age- and sex-adjusted regression models, and hypothesis-based interaction analyses.

Datasets

The study utilized data collected from the MAVIDOS trial participants. The primary dataset for this follow-up study comprised anthropometric and DXA measurements from 452 children at age 4. Maternal characteristics and pregnancy data were also used. No new datasets were introduced.

Key Insights and Ideas

  • Sustained Skeletal Benefit: The most significant finding is that maternal vitamin D supplementation during pregnancy appears to have a lasting positive impact on offspring bone mineral density, extending to at least age 4. This provides stronger evidence for a long-term benefit than the initial neonatal findings.
  • Synergistic Effects: The intervention's effect on bone mineral density was amplified in children with low milk intake and low levels of physical activity. This suggests that vitamin D supplementation might be particularly crucial for children who are not receiving adequate calcium from their diet or are less physically active, as these factors also play a role in bone health.
  • Lean Mass Association: Beyond bone density, there was also a trend towards increased lean mass in the supplemented group, suggesting a broader impact on musculoskeletal development.
  • Season of Birth Irrelevance at Age 4: Unlike the neonatal findings, the beneficial effects on bone mass at age 4 were observed across the entire cohort, irrespective of the season of birth. This indicates that the intervention's impact may become more generalized over time.

Key Results

  • Maternal vitamin D supplementation led to significantly greater WBLH aBMD in children at age 4 compared to placebo (0.477 vs. 0.470 g/cm², p = 0.048).
  • Associations were consistent for BMC and lean mass, though not always statistically significant.
  • The effect on aBMD was observed across the whole cohort, regardless of season of birth.
  • Interactions were observed: children with low milk intake and low physical activity showed a greater effect size from maternal vitamin D supplementation.
  • Child weight, height, and BMI were similar between the groups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Exclusion Criteria: Participants with baseline 25(OH)D levels below 25 nmol/L were excluded from the original trial, potentially limiting generalizability to populations with lower baseline vitamin D status.
  • Ethnic Diversity: The study population did not include a large representation of ethnic minorities, which could affect the generalizability of findings.
  • DXA Challenges: DXA assessment in children can be challenging due to movement artifacts, although the researchers employed methods to mitigate this.
  • Confounding Factors: While efforts were made to control for factors like height and weight, the complex interplay of diet, physical activity, and genetics in childhood bone development is acknowledged.
  • Follow-up Duration: The 4-year follow-up is a secondary analysis and does not represent the full long-term impact.

Future work includes ongoing follow-up of the MAVIDOS children to 6-8 years of age across all study centers and a planned further trial in Southampton to replicate these findings. The authors emphasize the need for further research to understand the long-term implications for fracture risk in adulthood.

Summary updated

Abstract

In the Maternal Vitamin D Osteoporosis Study (MAVIDOS) randomized trial, vitamin D supplementation in pregnancy did not lead to greater neonatal bone mass across the trial as a whole, but, in a prespecified secondary analysis by season of birth, led to greater neonatal bone mass among winter-born babies. Demonstrating persistence of this effect into childhood would increase confidence in a long-term benefit of this intervention. We investigated whether antenatal vitamin D supplementation increases offspring bone mineralization in early childhood in a prespecified, single-center follow-up of a double-blinded, multicenter, randomized controlled clinical trial based in the UK (MAVIDOS). A total of 1123 women in early pregnancy with a baseline 25-hydroxyvitamin D level 25-100 nmol/L from three research centers (2008-2014) were randomized to 1000 IU/d cholecalciferol or matched placebo from 14 weeks of gestation to delivery. Offspring born at the Southampton, UK research center were assessed at age 4 years (2013-2018). Anthropometry and dual-energy X-ray absorptiometry (DXA) were performed (yielding whole body less head [WBLH] bone mineral content [BMC], areal bone mineral density [aBMD], bone area [BA], and body composition). Of 723 children, 564 (78.0%) children attended the 4-year visit, 452 of whom had a useable DXA. Maternal vitamin D supplementation led to greater WBLH aBMD in the children compared with placebo (mean [95% confidence interval {CI}]: supplemented group: 0.477 (95% CI, 0.472-0.481) g/cm<sup>2</sup>; placebo group: 0.470 (95% CI, 0.466-0.475) g/cm<sup>2</sup>, <i>p</i> = 0.048). Associations were consistent for BMC and lean mass, and in age- and sex-adjusted models. Effects were observed across the whole cohort irrespective of season of birth. Maternal-child interactions were observed, with a greater effect size among children with low milk intake and low levels of physical activity. Child weight, height, and body mass index (BMI) were similar by maternal randomization group. These findings suggest a sustained beneficial effect of maternal vitamin D supplementation in pregnancy on offspring aBMD at age 4 years, but will require replication in other trials. © 2022 The Authors. <i>JBMR Plus</i> published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
BibTeX
@inproceedings{curtis2022pregnancy,
  author = {Elizabeth Curtis and Rebecca J Moon and Stefania D’Angelo and Sarah Crozier and Nicholas Bishop and Jaya Sujatha Gopal‐Kothandapani and Stephen Kennedy and Aris T. Papageorghiou and Robert Fraser and Saurabh Gandhi and Inez Schoenmakers and Ann Prentice and Hazel Inskip and Keith M. Godfrey and M K Javaid and Richard Eastell and Cyrus Cooper and Nicholas C. Harvey and the MAVIDOS Trial Group},
  title = {{Pregnancy Vitamin D Supplementation and Childhood Bone Mass at Age 4 Years: Findings From the Maternal Vitamin D Osteoporosis Study (MAVIDOS) Randomized Controlled Trial}},
  booktitle = {JBMR},
  year = {2022},
  doi = {10.1002/jbm4.10651},
}
Figure